TimesSquare Capital Management LLC Grows Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

TimesSquare Capital Management LLC lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 37.6% during the third quarter, Holdings Channel reports. The fund owned 114,222 shares of the company’s stock after buying an additional 31,183 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Krystal Biotech were worth $20,792,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Jamison Private Wealth Management Inc. acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at about $28,000. GAMMA Investing LLC boosted its position in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares in the last quarter. Key Financial Inc acquired a new stake in shares of Krystal Biotech during the 2nd quarter worth approximately $28,000. Blue Trust Inc. increased its holdings in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Krystal Biotech in the 3rd quarter valued at $53,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of recent analyst reports. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Stifel Nicolaus upped their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Citigroup upped their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $197.00.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $199.61 on Monday. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The stock’s fifty day moving average is $181.29 and its two-hundred day moving average is $180.71. The firm has a market capitalization of $5.74 billion, a P/E ratio of 112.77 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.67) earnings per share. On average, equities analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).